News Center

News Center

News Center

Duality Biologics Orally Presents Phase 1 Healthy Volunteer Data for First-in-Class BDCA2-Targeted ADC DB-2304 at Autumn Immunology Conference 2025

2024-12-06

Duality Biologics and BioNTech Presented Positive Interim Data for Investigational B7-H3 Antibody-Drug Conjugate BNT324/DB-1311 in Advanced Solid Tumors at the ESMO Asia Congress 2024
2024-12-03

Duality Biologics and GSK Enter Exclusive Option Agreement for a Novel Antibody-drug Conjugate (DB-1324)
2024-11-26

Duality Biologics Announces Expansion of Adcendo ApS Collaboration Through Option Exercise of Strategic License Agreement
2024-11-08

11th Annual World ADC Awards - Proposal Sheet ML
2024-11-04

DualityBio's First-in-Class ADC Drug DB-2304 for Autoimmune Diseases Completes First Global Patient Dosing in Phase I Clinical Trial
2024-09-09

DualityBio's Next-Generation Bispecific ADC DB-1419 Receives FDA IND Approval and Completes First Global Patient Dosing

«
1
2
3
4
»

Scan the code to follow DualityBio official wechat

Phone：021-2601 8730

Address：Full floor, 11th floor, tower a, Datang International Plaza,China

Construction Engineering Group, No. 868 Yinghua Road, Pudong New Area, Shanghai